Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Inactivating Mutations

NCT04770246 is registered in ClinicalTrials.gov with Taiho Oncology, Inc. as lead sponsor.

NCT NCT04770246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04770246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Inactivating Mutations
Lead sponsor
Taiho Oncology, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
March 31, 2021
Completion date
March 6, 2023
Enrollment
17 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors irrespective of gene alterations, advanced or metastatic solid tumors with germline pten inactivating mutations